ALNYLAM PHARMACEUTICALS, INC. ALNY Financial Statement Data


2025 Q2

Submissions

Field Row 1
adsh 0001178670-25-000052
cik 1178670
name ALNYLAM PHARMACEUTICALS, INC.
sic 2834
countryba US
stprba MA
cityba CAMBRIDGE
zipba 02142
bas1 675 WEST KENDALL STREET
bas2 HENRI A. TERMEER SQUARE
baph (617) 551-8200
countryma US
stprma MA
cityma CAMBRIDGE
zipma 02142
mas1 675 WEST KENDALL STREET
mas2 HENRI A. TERMEER SQUARE
countryinc
stprinc
ein 770602661
former ALNYLAM PHARMACEUTICALS INC
changed 20020724
afs 1-LAF
wksi 0
fye 1231
form 10-Q
period 20250331
fy 2025
fp Q1
filed 20250501
accepted 2025-05-01 08:15:00.0
prevrpt 0
detail 1
instance alny-20250331_htm.xml
nciks 1
aciks

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
cik Central Index Key (CIK). Ten digit number assigned by the SEC to each registrant that submits filings.
name Name of registrant. This corresponds to the name of the legal entity as recorded in EDGAR as of the filing date.
sic Standard Industrial Classification (SIC). Four digit code assigned by the SEC as of the filing date, indicating the registrant’s type of business.
countryba The ISO 3166-1 country of the registrant's business address.
stprba The state or province of the registrant’s business address, if field countryba is US or CA.
cityba The city of the registrant's business address.
zipba The zip code of the registrant’s business address.
bas1 The first line of the street of the registrant’s business address.
bas2 The second line of the street of the registrant’s business address.
baph The phone number of the registrant’s business address.
countryma The ISO 3166-1 country of the registrant's mailing address.
stprma The state or province of the registrant’s mailing address, if field countryma is US or CA.
cityma The city of the registrant's mailing address.
zipma The zip code of the registrant’s mailing address.
mas1 The first line of the street of the registrant’s mailing address.
mas2 The second line of the street of the registrant’s mailing address.
countryinc The ISO 3166-1 country of incorporation for the registrant.
stprinc The state or province of incorporation for the registrant, if countryinc is US or CA.
ein Employee Identification Number, 9 digit identification number assigned by the Internal Revenue Service to business entities operating in the United States.
former Most recent former name of the registrant, if any.
changed Date of change from the former name, if any.
afs Filer status with the SEC at the time of submission:
1-LAF=Large Accelerated, 2-ACC=Accelerated, 3-SRA=Smaller Reporting Accelerated, 4-NON=Non-Accelerated, 5-SML=Smaller Reporting Filer, NULL=not assigned.
wksi Well Known Seasoned Issuer (WKSI). An issuer that meets specific SEC requirements at some point during a 60-day period preceding the date the issuer satisfies its obligation to update its shelf registration statement.
fye Fiscal Year End Date, rounded to nearest month-end.
form The submission type of the registrant’s filing.
period Balance Sheet Date, rounded to nearest month-end.
fy Fiscal Year Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8).
fp Fiscal Period Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8) within Fiscal Year.
filed The date of the registrant’s filing with the Commission.
accepted The acceptance date and time of the registrant’s filing with the Commission.
prevrpt Previous Report – TRUE indicates that the submission information was subsequently amended.
detail TRUE indicates that the XBRL submission contains quantitative disclosures within the footnotes and schedules at the required detail level (e.g., each amount).
instance The name of the submitted XBRL Instance Document. The name often begins with the company ticker symbol.
nciks Number of Central Index Keys (CIK) of registrants (i.e., business units) included in the consolidating entity’s submitted filing.
aciks Additional CIKs of co-registrants included in a consolidating entity’s EDGAR submission, separated by spaces. If there are no other co-registrants (i.e., nciks=1), the value of aciks is NULL. For a very small number of filers, the entire list of co-registrants is too long to fit in the field. Where this is the case, users should refer to the complete submission file for all CIK information.

Numbers

adsh ddate tag value uom qtrs version segments coreg footnote
0001178670-25-000052 20241231 Inventory Net 78509000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20250331 Accounts Receivable Net Current 418035000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20250331 Accrued Liabilities Current 704165000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20241231 Accumulated Other Comprehensive Income Loss Net Of Tax -34518000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20241231 Additional Paid In Capital Common Stock 7388061000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20250331 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 57840000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20250331 Assets 4213811000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20240331 Capital Expenditures Incurred But Not Yet Paid 2242000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20231231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 814884000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20241231 Common Stock Shares Issued 129294000.0000 shares 0 us-gaap/2024
0001178670-25-000052 20241231 Common Stock Shares Outstanding 129294000.0000 shares 0 us-gaap/2024
0001178670-25-000052 20250331 Common Stock Shares Outstanding 130311000.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0001178670-25-000052 20250331 Contract With Customer Liability Current 28160000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20241231 Convertible Debt Noncurrent 1024621000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20250331 Earnings Per Share Diluted -0.4400 USD 1 us-gaap/2024
0001178670-25-000052 20241231 Equity Securities Fv Ni 0.0000 USD 0 us-gaap/2024 Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level3; Fair Value By Measurement Frequency= Fair Value Measurements Recurring;
0001178670-25-000052 20250331 Equity Securities Fv Ni 7200000.0000 USD 0 us-gaap/2024 Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level1; Fair Value By Measurement Frequency= Fair Value Measurements Recurring;
0001178670-25-000052 20250331 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest -41596000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20240331 Increase Decrease In Accounts Payable And Accrued Liabilities -4865000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20240331 Increase Decrease In Contract With Customer Liability -28563000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20240331 Interest Paid Net 30945000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20250331 Operating Income Loss 18077000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20250331 Other Comprehensive Income Loss Net Of Tax -2999000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20240331 Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax -3568000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20250331 Other Operating Activities Cash Flow Statement -19354000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20240331 Payments To Acquire Restricted Investments 39975000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20250331 Payments To Acquire Restricted Investments 48825000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20250331 Preferred Stock Shares Authorized 5000000.0000 shares 0 us-gaap/2024
0001178670-25-000052 20250331 Research And Development Expense 265122000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20250331 Research And Development Expense 29700000.0000 USD 1 us-gaap/2024 Counterparty Name= Roche; Type Of Arrangement= Roche Collaboration And License Agreement;
0001178670-25-000052 20250331 Research And Development Expense 127343000.0000 USD 1 us-gaap/2024 Research And Development Expense= Clinical Research And Outside Services;
0001178670-25-000052 20240331 Revenue From Contract With Customer Excluding Assessed Tax 195241000.0000 USD 1 us-gaap/2024 Product Or Service= Amvuttra;
0001178670-25-000052 20240331 Revenue From Contract With Customer Excluding Assessed Tax 58056000.0000 USD 1 us-gaap/2024 Product Or Service= G I V L A A R I;
0001178670-25-000052 20250331 Revenue From Contract With Customer Excluding Assessed Tax 30000000.0000 USD 0 us-gaap/2024 Counterparty Name= Vir Biotechnology Inc.; Product Or Service= Collaborations;
0001178670-25-000052 20250331 Revenue From Contract With Customer Excluding Assessed Tax 2400000.0000 USD 1 us-gaap/2024 Counterparty Name= Regeneron Pharmaceuticals Incorporation; Product Or Service= Regeneron Technology Transfer Obligation; Type Of Arrangement= Global Strategic Collaboration;
0001178670-25-000052 20250331 Revenue From Contract With Customer Excluding Assessed Tax 51039000.0000 USD 1 us-gaap/2024 Counterparty Name= Regeneron Pharmaceuticals Incorporation; Type Of Arrangement= Collaborative Arrangement;
0001178670-25-000052 20250331 Revenue From Contract With Customer Excluding Assessed Tax 0.0000 USD 1 us-gaap/2024 Counterparty Name= Roche; Product Or Service= Technology Transfer Obligation; Type Of Arrangement= Roche Collaboration And License Agreement;
0001178670-25-000052 20250331 Revenue From Contract With Customer Excluding Assessed Tax 15572000.0000 USD 1 us-gaap/2024 Geographical= U S; Product Or Service= O N P A T T R O;
0001178670-25-000052 20250331 Revenue From Contract With Customer Excluding Assessed Tax 66968000.0000 USD 1 us-gaap/2024 Product Or Service= G I V L A A R I;
0001178670-25-000052 20240331 Right Of Use Asset Obtained In Exchange For Operating Lease Liability 774000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20250331 Right Of Use Asset Obtained In Exchange For Operating Lease Liability 9826000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20231231 Stockholders Equity -32792000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Loss On Investment In Joint Venture;
0001178670-25-000052 20231231 Stockholders Equity 10622000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Translation Adjustment;
0001178670-25-000052 20240331 Stockholders Equity -32792000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Loss On Investment In Joint Venture;
0001178670-25-000052 20241231 Stockholders Equity -32792000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Loss On Investment In Joint Venture;
0001178670-25-000052 20241231 Stockholders Equity 1293000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0001178670-25-000052 20240331 Stock Issued During Period Value Stock Options Exercised 24765000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20241231 Accounts Receivable Net Current 405308000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20241231 Accounts Payable Current 88415000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20250331 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 57840000.0000 USD 1 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001178670-25-000052 20241231 Available For Sale Securities Debt Securities Current 1719920000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20250331 Available For Sale Securities Debt Securities Current 1605368000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20240331 Cash And Cash Equivalents At Carrying Value 681879000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20240331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect -130165000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20241231 Contract With Customer Liability Current 55481000.0000 USD 0 us-gaap/2024 Type Of Arrangement= Collaborative Arrangement;
0001178670-25-000052 20250331 Contract With Customer Liability Current 27300000.0000 USD 0 us-gaap/2024 Counterparty Name= Regeneron Pharmaceuticals Incorporation; Product Or Service= Research Services Obligation; Type Of Arrangement= Global Strategic Collaboration;
0001178670-25-000052 20240331 Cost Of Goods And Services Sold 54613000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20241231 Deferred Income Tax Assets Net 116863000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20240331 Deferred Income Tax Expense Benefit 454000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20250331 Derivative Liabilities Noncurrent 422434000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20250331 Earnings Per Share Basic -0.4400 USD 1 us-gaap/2024
0001178670-25-000052 20240331 Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents -9941000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20250331 Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 14058000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20241231 Equity Securities Fv Ni 0.0000 USD 0 us-gaap/2024 Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level2; Fair Value By Measurement Frequency= Fair Value Measurements Recurring;
0001178670-25-000052 20240331 Equity Securities Fv Ni Gain Loss 78000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20250331 Income Taxes Paid Net 2969000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20240331 Interest Expense Nonoperating 35253000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20250331 Net Income Loss -57479000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20240331 Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax -78000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20250331 Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Reclassification Adjustments Net Of Tax -55000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20241231 Other Liabilities Noncurrent 4969000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20250331 Preferred Stock Value 0.0000 USD 0 us-gaap/2024
0001178670-25-000052 20250331 Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options 49365000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20240331 Revenue From Contract With Customer Excluding Assessed Tax 1700000.0000 USD 1 us-gaap/2024 Counterparty Name= Regeneron Pharmaceuticals Incorporation; Product Or Service= C5 License Obligation; Type Of Arrangement= Global Strategic Collaboration;
0001178670-25-000052 20240331 Revenue From Contract With Customer Excluding Assessed Tax 16539000.0000 USD 1 us-gaap/2024 Geographical= U S; Product Or Service= O N P A T T R O;
0001178670-25-000052 20250331 Revenue From Contract With Customer Excluding Assessed Tax 7376000.0000 USD 1 us-gaap/2024 Geographical= Non U S Or Europe; Product Or Service= O N P A T T R O;
0001178670-25-000052 20250331 Revenue From Contract With Customer Excluding Assessed Tax 14109000.0000 USD 1 us-gaap/2024 Geographical= U S; Product Or Service= O X L U M O;
0001178670-25-000052 20250331 Revenue From Contract With Customer Excluding Assessed Tax 99185000.0000 USD 1 us-gaap/2024 Product Or Service= Collaborations;
0001178670-25-000052 20250331 Revenue From Contract With Customer Excluding Assessed Tax 468538000.0000 USD 1 us-gaap/2024 Product Or Service= Product;
0001178670-25-000052 20250331 Revenue From Contract With Customer Excluding Assessed Tax 26466000.0000 USD 1 us-gaap/2024 Product Or Service= Royalty;
0001178670-25-000052 20241231 Royalty Liability Noncurrent 1447371000.0000 USD 0 0001178670-25-000052 Counterparty Name= Blackstone Group Inc; Type Of Arrangement= Collaborative Arrangement;
0001178670-25-000052 20250331 Royalty Liability Noncurrent 1338821000.0000 USD 0 0001178670-25-000052
0001178670-25-000052 20250331 Selling General And Administrative Expense 64687000.0000 USD 1 us-gaap/2024 Selling General And Administrative Expense= Consulting And Professional Services;
0001178670-25-000052 20240331 Stockholders Equity 10544000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Translation Adjustment;
0001178670-25-000052 20241231 Stockholders Equity 7388061000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001178670-25-000052 20250331 Stock Issued During Period Shares Share Based Compensation Gross 594000.0000 shares 1 us-gaap/2024 Equity Components= Common Stock;
0001178670-25-000052 20241231 Accounts Receivable Net Current 102743000.0000 USD 0 us-gaap/2024 Type Of Arrangement= Collaborative Arrangement;
0001178670-25-000052 20250331 Capital Expenditures Incurred But Not Yet Paid 3650000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20241231 Common Stock Shares Authorized 250000000.0000 shares 0 us-gaap/2024
0001178670-25-000052 20250331 Common Stock Shares Issued 130311000.0000 shares 0 us-gaap/2024
0001178670-25-000052 20241231 Common Stock Shares Outstanding 129294000.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0001178670-25-000052 20250331 Common Stock Shares Outstanding 130311000.0000 shares 0 us-gaap/2024
0001178670-25-000052 20250331 Convertible Debt Noncurrent 1025566000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20240331 Costs And Expenses 537768000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20250331 Derivative Liabilities Current 118095000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20250331 Equity Securities Fv Ni 7200000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20240331 Income Taxes Paid Net 1987000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20240331 Income Tax Expense Benefit 2348000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20240331 Increase Decrease In Accounts Receivable -410000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20250331 Increase Decrease In Contract With Customer Liability -27321000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20250331 Increase Decrease In Inventories -6215000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20250331 Liabilities 4098376000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20241231 Liabilities Current 1186272000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20240331 Net Cash Provided By Used In Financing Activities 28911000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20250331 Net Cash Provided By Used In Financing Activities 44084000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20240331 Nonoperating Income Expense -20152000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20241231 Operating Lease Right Of Use Asset 191148000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20241231 Other Assets Noncurrent 65310000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20240331 Other Comprehensive Income Loss Net Of Tax -3613000.0000 USD 1 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001178670-25-000052 20250331 Other Liabilities Noncurrent 5871000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20240331 Payments To Acquire Property Plant And Equipment 12973000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20241231 Preferred Stock Par Or Stated Value Per Share 0.0100 USD 0 us-gaap/2024
0001178670-25-000052 20241231 Preferred Stock Shares Authorized 5000000.0000 shares 0 us-gaap/2024
0001178670-25-000052 20241231 Preferred Stock Shares Outstanding 0.0000 shares 0 us-gaap/2024
0001178670-25-000052 20240331 Proceeds From Sale Of Restricted Investments 39975000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20250331 Proceeds From Sale Of Restricted Investments 48825000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20250331 Property Plant And Equipment Net 498684000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20250331 Research And Development Expense 38592000.0000 USD 1 us-gaap/2024 Research And Development Expense= Occupancy And All Other Costs;
0001178670-25-000052 20240331 Revenue From Contract With Customer Excluding Assessed Tax 7151000.0000 USD 1 us-gaap/2024 Counterparty Name= Roche; Product Or Service= Development Services Obligation; Type Of Arrangement= Roche Collaboration And License Agreement;
0001178670-25-000052 20240331 Revenue From Contract With Customer Excluding Assessed Tax 0.0000 USD 1 us-gaap/2024 Counterparty Name= Roche; Product Or Service= Technology Transfer Obligation; Type Of Arrangement= Roche Collaboration And License Agreement;
0001178670-25-000052 20240331 Revenue From Contract With Customer Excluding Assessed Tax 4010000.0000 USD 1 us-gaap/2024 Geographical= Non U S Or Europe; Product Or Service= G I V L A A R I;
0001178670-25-000052 20240331 Revenue From Contract With Customer Excluding Assessed Tax 7988000.0000 USD 1 us-gaap/2024 Geographical= Non U S Or Europe; Product Or Service= O N P A T T R O;
0001178670-25-000052 20240331 Revenue From Contract With Customer Excluding Assessed Tax 118548000.0000 USD 1 us-gaap/2024 Product Or Service= Collaborations;
0001178670-25-000052 20250331 Revenue From Contract With Customer Excluding Assessed Tax 15840000.0000 USD 1 us-gaap/2024 Counterparty Name= Roche; Type Of Arrangement= Roche Collaboration And License Agreement;
0001178670-25-000052 20250331 Revenue From Contract With Customer Excluding Assessed Tax 18544000.0000 USD 1 us-gaap/2024 Geographical= Europe; Product Or Service= G I V L A A R I;
0001178670-25-000052 20250331 Revenue From Contract With Customer Excluding Assessed Tax 26541000.0000 USD 1 us-gaap/2024 Geographical= Europe; Product Or Service= O N P A T T R O;
0001178670-25-000052 20250331 Revenue From Contract With Customer Excluding Assessed Tax 4630000.0000 USD 1 us-gaap/2024 Geographical= Non U S Or Europe; Product Or Service= G I V L A A R I;
0001178670-25-000052 20250331 Revenue From Contract With Customer Excluding Assessed Tax 309992000.0000 USD 1 us-gaap/2024 Product Or Service= Amvuttra;
0001178670-25-000052 20240331 Selling General And Administrative Expense 210797000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20240331 Stockholders Equity -2020000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Net Unrealized Investment Gain Loss;
0001178670-25-000052 20240331 Stockholders Equity 1265000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0001178670-25-000052 20241231 Stockholders Equity -7287748000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0001178670-25-000052 20250331 Stockholders Equity 2574000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Net Unrealized Investment Gain Loss;
0001178670-25-000052 20250331 Stockholders Equity 7496876000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001178670-25-000052 20250331 Stock Issued During Period Value Stock Options Exercised 50985000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20240331 Weighted Average Number Of Diluted Shares Outstanding 126138000.0000 shares 1 us-gaap/2024
0001178670-25-000052 20250331 Accounts Receivable Net Current 311926000.0000 USD 0 us-gaap/2024 Product Or Service= Product;
0001178670-25-000052 20250331 Additional Paid In Capital Common Stock 7496876000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20240331 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 46155000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20240331 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 46155000.0000 USD 1 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001178670-25-000052 20241231 Cash And Cash Equivalents At Carrying Value 966428000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20250331 Cash And Cash Equivalents At Carrying Value 1019654000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20241231 Common Stock Value 1293000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20250331 Comprehensive Income Net Of Tax -60478000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20241231 Contract With Customer Liability Current 55481000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20241231 Contract With Customer Liability Current 41200000.0000 USD 0 us-gaap/2024 Counterparty Name= Regeneron Pharmaceuticals Incorporation; Product Or Service= Research Services Obligation; Type Of Arrangement= Global Strategic Collaboration;
0001178670-25-000052 20241231 Derivative Liabilities Current 93780000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20241231 Equity Securities Fv Ni 8156000.0000 USD 0 us-gaap/2024 Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level1; Fair Value By Measurement Frequency= Fair Value Measurements Recurring;
0001178670-25-000052 20240331 Increase Decrease In Inventories -22000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20250331 Interest Paid Net 66933000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20250331 Investment Income Interest 28673000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20241231 Liabilities And Stockholders Equity 4239983000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20250331 Net Income Loss -57479000.0000 USD 1 us-gaap/2024 Equity Components= Retained Earnings;
0001178670-25-000052 20250331 Non Cash Interest Expense On Sale Of Future Royalties 34962000.0000 USD 1 0001178670-25-000052
0001178670-25-000052 20241231 Operating Lease Liability Current 41886000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20240331 Other Operating Activities Cash Flow Statement -6513000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20250331 Payments For Proceeds From Derivative Instrument Financing Activities 5281000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20241231 Preferred Stock Value 0.0000 USD 0 us-gaap/2024
0001178670-25-000052 20240331 Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options 25859000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20240331 Proceeds From Sale And Maturity Of Marketable Securities 365468000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20240331 Research And Development Expense 260995000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20240331 Research And Development Expense 96424000.0000 USD 1 us-gaap/2024 Research And Development Expense= Compensation And Related;
0001178670-25-000052 20250331 Research And Development Expense 18900000.0000 USD 1 us-gaap/2024 Counterparty Name= Regeneron Pharmaceuticals Incorporation; Type Of Arrangement= Global Strategic Collaboration;
0001178670-25-000052 20250331 Restricted Investments Noncurrent 68592000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20250331 Retained Earnings Accumulated Deficit -7345227000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20240331 Revenue From Contract With Customer Excluding Assessed Tax 65000000.0000 USD 1 us-gaap/2024 Counterparty Name= Roche; Product Or Service= License Obligation; Type Of Arrangement= Roche Collaboration And License Agreement;
0001178670-25-000052 20240331 Revenue From Contract With Customer Excluding Assessed Tax 72151000.0000 USD 1 us-gaap/2024 Counterparty Name= Roche; Type Of Arrangement= Roche Collaboration And License Agreement;
0001178670-25-000052 20240331 Revenue From Contract With Customer Excluding Assessed Tax 15315000.0000 USD 1 us-gaap/2024 Geographical= Europe; Product Or Service= G I V L A A R I;
0001178670-25-000052 20240331 Revenue From Contract With Customer Excluding Assessed Tax 69217000.0000 USD 1 us-gaap/2024 Product Or Service= O N P A T T R O;
0001178670-25-000052 20240331 Revenue From Contract With Customer Excluding Assessed Tax 264458000.0000 USD 1 us-gaap/2024 Product Or Service= T T R;
0001178670-25-000052 20250331 Revenue From Contract With Customer Excluding Assessed Tax 0.0000 USD 1 us-gaap/2024 Counterparty Name= Novartis; Type Of Arrangement= Collaborative Arrangement;
0001178670-25-000052 20250331 Revenue From Contract With Customer Excluding Assessed Tax 15840000.0000 USD 1 us-gaap/2024 Counterparty Name= Roche; Product Or Service= Development Services Obligation; Type Of Arrangement= Roche Collaboration And License Agreement;
0001178670-25-000052 20250331 Revenue From Contract With Customer Excluding Assessed Tax 197964000.0000 USD 1 us-gaap/2024 Geographical= U S; Product Or Service= Amvuttra;
0001178670-25-000052 20250331 Revenue From Contract With Customer Excluding Assessed Tax 109057000.0000 USD 1 us-gaap/2024 Product Or Service= Rare;
0001178670-25-000052 20240331 Selling General And Administrative Expense 56759000.0000 USD 1 us-gaap/2024 Selling General And Administrative Expense= Consulting And Professional Services;
0001178670-25-000052 20250331 Share Based Compensation 56712000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20231231 Stockholders Equity 1259000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0001178670-25-000052 20240331 Stockholders Equity -219272000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20241231 Stockholders Equity -34518000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001178670-25-000052 20250331 Stockholders Equity 115435000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20250331 Stockholders Equity -32792000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Loss On Investment In Joint Venture;
0001178670-25-000052 20250331 Stockholders Equity -3105000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Translation Adjustment;
0001178670-25-000052 20250331 Stockholders Equity 1303000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0001178670-25-000052 20250331 Stock Issued During Period Value Share Based Compensation Gross -6000.0000 USD 1 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001178670-25-000052 20240331 Stock Issued During Period Value Stock Options Exercised 2000.0000 USD 1 us-gaap/2024 Equity Components= Common Stock;
0001178670-25-000052 20241231 Accounts Receivable Net Current 269900000.0000 USD 0 us-gaap/2024 Product Or Service= Product;
0001178670-25-000052 20250331 Accounts Receivable Net Current 80422000.0000 USD 0 us-gaap/2024 Type Of Arrangement= Collaborative Arrangement;
0001178670-25-000052 20250331 Assets Current 3268258000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20250331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 1022249000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20250331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect 53597000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20231231 Common Stock Shares Outstanding 125794000.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0001178670-25-000052 20240331 Earnings Per Share Basic -0.5200 USD 1 us-gaap/2024
0001178670-25-000052 20250331 Equity Securities Fv Ni 0.0000 USD 0 us-gaap/2024 Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level3; Fair Value By Measurement Frequency= Fair Value Measurements Recurring;
0001178670-25-000052 20240331 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest -63587000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20240331 Increase Decrease In Prepaid Deferred Expense And Other Assets 75462000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20250331 Interest Expense Nonoperating 38646000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20241231 Liabilities 4172895000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20250331 Net Cash Provided By Used In Operating Activities -118314000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20240331 Net Income Loss -65935000.0000 USD 1 us-gaap/2024 Equity Components= Retained Earnings;
0001178670-25-000052 20240331 Non Cash Interest Expense On Sale Of Future Royalties 31565000.0000 USD 1 0001178670-25-000052
0001178670-25-000052 20250331 Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax -4084000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20250331 Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax 1030000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20240331 Other Nonoperating Income Expense -14544000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20250331 Payments To Acquire Available For Sale Securities Debt 401642000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20241231 Preferred Stock Shares Issued 0.0000 shares 0 us-gaap/2024
0001178670-25-000052 20241231 Property Plant And Equipment Net 502784000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20241231 Restricted Investments Noncurrent 68593000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20240331 Revenue From Contract With Customer Excluding Assessed Tax 14516000.0000 USD 1 us-gaap/2024 Counterparty Name= Novartis; Type Of Arrangement= Collaborative Arrangement;
0001178670-25-000052 20240331 Revenue From Contract With Customer Excluding Assessed Tax 14700000.0000 USD 1 us-gaap/2024 Counterparty Name= Regeneron Pharmaceuticals Incorporation; Product Or Service= Research Services Obligation; Type Of Arrangement= Global Strategic Collaboration;
0001178670-25-000052 20240331 Revenue From Contract With Customer Excluding Assessed Tax 43733000.0000 USD 1 us-gaap/2024 Geographical= Europe; Product Or Service= Amvuttra;
0001178670-25-000052 20240331 Revenue From Contract With Customer Excluding Assessed Tax 365163000.0000 USD 1 us-gaap/2024 Product Or Service= Product;
0001178670-25-000052 20250331 Revenue From Contract With Customer Excluding Assessed Tax 594189000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20250331 Revenue From Contract With Customer Excluding Assessed Tax 0.0000 USD 1 us-gaap/2024 Counterparty Name= Roche; Product Or Service= License Obligation; Type Of Arrangement= Roche Collaboration And License Agreement;
0001178670-25-000052 20250331 Revenue From Contract With Customer Excluding Assessed Tax 17056000.0000 USD 1 us-gaap/2024 Counterparty Name= Roche; Type Of Arrangement= Collaborative Arrangement;
0001178670-25-000052 20250331 Revenue From Contract With Customer Excluding Assessed Tax 49489000.0000 USD 1 us-gaap/2024 Product Or Service= O N P A T T R O;
0001178670-25-000052 20241231 Royalty Liability Current 113018000.0000 USD 0 0001178670-25-000052
0001178670-25-000052 20250331 Royalty Liability Noncurrent 1420614000.0000 USD 0 0001178670-25-000052 Counterparty Name= Blackstone Group Inc; Type Of Arrangement= Collaborative Arrangement;
0001178670-25-000052 20250331 Selling General And Administrative Expense 131437000.0000 USD 1 us-gaap/2024 Selling General And Administrative Expense= Compensation And Related;
0001178670-25-000052 20231231 Stockholders Equity -2753000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Defined Benefit Plans Adjustment;
0001178670-25-000052 20231231 Stockholders Equity 1548000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Net Unrealized Investment Gain Loss;
0001178670-25-000052 20231231 Stockholders Equity 6811063000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001178670-25-000052 20240331 Stockholders Equity -26988000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001178670-25-000052 20240331 Stock Issued During Period Value Share Based Compensation Gross 0.0000 USD 1 us-gaap/2024
0001178670-25-000052 20240331 Stock Issued During Period Value Stock Options Exercised 24763000.0000 USD 1 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001178670-25-000052 20240331 Weighted Average Number Of Shares Outstanding Basic 126138000.0000 shares 1 us-gaap/2024
0001178670-25-000052 20250331 Weighted Average Number Of Shares Outstanding Basic 129676000.0000 shares 1 us-gaap/2024
0001178670-25-000052 20241231 Accrued Liabilities Current 793692000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20250331 Accumulated Other Comprehensive Income Loss Net Of Tax -37517000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20250331 Operating Lease Right Of Use Asset 197233000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20240331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 684719000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20241231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 968652000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20240331 Change In Fair Value Of Liability Obligation -8586000.0000 USD 1 0001178670-25-000052
0001178670-25-000052 20250331 Common Stock Shares Authorized 250000000.0000 shares 0 us-gaap/2024
0001178670-25-000052 20250331 Contract With Customer Liability Current 28160000.0000 USD 0 us-gaap/2024 Type Of Arrangement= Collaborative Arrangement;
0001178670-25-000052 20240331 Cost Of Collaboration Manufacturing And Royalties 11363000.0000 USD 1 0001178670-25-000052
0001178670-25-000052 20250331 Cost Of Collaboration Manufacturing And Royalties 858000.0000 USD 1 0001178670-25-000052
0001178670-25-000052 20250331 Cost Of Goods And Services Sold 70183000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20250331 Costs And Expenses 576112000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20250331 Deferred Income Tax Assets Net 107224000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20250331 Depreciation Amortization And Accretion Net 14405000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20241231 Derivative Liabilities Noncurrent 393139000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20241231 Equity Securities Fv Ni 8156000.0000 USD 0 us-gaap/2024 Fair Value By Measurement Frequency= Fair Value Measurements Recurring;
0001178670-25-000052 20250331 Equity Securities Fv Ni 0.0000 USD 0 us-gaap/2024 Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level2; Fair Value By Measurement Frequency= Fair Value Measurements Recurring;
0001178670-25-000052 20250331 Equity Securities Fv Ni 7200000.0000 USD 0 us-gaap/2024 Fair Value By Measurement Frequency= Fair Value Measurements Recurring;
0001178670-25-000052 20250331 Income Tax Expense Benefit 15883000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20240331 Investment Income Interest 29645000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20240331 Net Cash Provided By Used In Investing Activities -67620000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20240331 Net Cash Provided By Used In Operating Activities -81515000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20240331 Other Comprehensive Income Loss Net Of Tax -3613000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20240331 Payments To Acquire Available For Sale Securities Debt 420115000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20250331 Proceeds From Sale And Maturity Of Marketable Securities 524381000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20240331 Research And Development Expense 18700000.0000 USD 1 us-gaap/2024 Counterparty Name= Regeneron Pharmaceuticals Incorporation; Type Of Arrangement= Global Strategic Collaboration;
0001178670-25-000052 20240331 Revenue From Contract With Customer Excluding Assessed Tax 74680000.0000 USD 1 us-gaap/2024 Counterparty Name= Roche; Type Of Arrangement= Collaborative Arrangement;
0001178670-25-000052 20240331 Revenue From Contract With Customer Excluding Assessed Tax 7890000.0000 USD 1 us-gaap/2024 Geographical= Non U S Or Europe; Product Or Service= O X L U M O;
0001178670-25-000052 20240331 Revenue From Contract With Customer Excluding Assessed Tax 130238000.0000 USD 1 us-gaap/2024 Geographical= U S; Product Or Service= Amvuttra;
0001178670-25-000052 20240331 Revenue From Contract With Customer Excluding Assessed Tax 38731000.0000 USD 1 us-gaap/2024 Geographical= U S; Product Or Service= G I V L A A R I;
0001178670-25-000052 20240331 Revenue From Contract With Customer Excluding Assessed Tax 13332000.0000 USD 1 us-gaap/2024 Geographical= U S; Product Or Service= O X L U M O;
0001178670-25-000052 20240331 Revenue From Contract With Customer Excluding Assessed Tax 42649000.0000 USD 1 us-gaap/2024 Product Or Service= O X L U M O;
0001178670-25-000052 20240331 Revenue From Contract With Customer Excluding Assessed Tax 100705000.0000 USD 1 us-gaap/2024 Product Or Service= Rare;
0001178670-25-000052 20250331 Revenue From Contract With Customer Excluding Assessed Tax 21500000.0000 USD 1 us-gaap/2024 Counterparty Name= Regeneron Pharmaceuticals Incorporation; Product Or Service= C5 License Obligation; Type Of Arrangement= Global Strategic Collaboration;
0001178670-25-000052 20250331 Revenue From Contract With Customer Excluding Assessed Tax 80088000.0000 USD 1 us-gaap/2024 Geographical= Europe; Product Or Service= Amvuttra;
0001178670-25-000052 20250331 Revenue From Contract With Customer Excluding Assessed Tax 31940000.0000 USD 1 us-gaap/2024 Geographical= Non U S Or Europe; Product Or Service= Amvuttra;
0001178670-25-000052 20250331 Revenue From Contract With Customer Excluding Assessed Tax 42089000.0000 USD 1 us-gaap/2024 Product Or Service= O X L U M O;
0001178670-25-000052 20250331 Royalty Liability Current 81793000.0000 USD 0 0001178670-25-000052
0001178670-25-000052 20250331 Selling General And Administrative Expense 43825000.0000 USD 1 us-gaap/2024 Selling General And Administrative Expense= Occupancy And All Other Costs;
0001178670-25-000052 20231231 Stockholders Equity -23375000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001178670-25-000052 20231231 Stockholders Equity -7009591000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0001178670-25-000052 20240331 Stockholders Equity -7075526000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0001178670-25-000052 20241231 Stockholders Equity -4249000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Defined Benefit Plans Adjustment;
0001178670-25-000052 20241231 Stockholders Equity 1544000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Net Unrealized Investment Gain Loss;
0001178670-25-000052 20250331 Stockholders Equity -4194000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Defined Benefit Plans Adjustment;
0001178670-25-000052 20240331 Stock Issued During Period Value Share Based Compensation Gross -4000.0000 USD 1 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001178670-25-000052 20250331 Stock Issued During Period Value Share Based Compensation Gross 0.0000 USD 1 us-gaap/2024
0001178670-25-000052 20250331 Stock Issued During Period Value Stock Options Exercised 50981000.0000 USD 1 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001178670-25-000052 20250331 Accounts Payable Current 97399000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20241231 Assets 4239983000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20241231 Assets Current 3295285000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20241231 Commitments And Contingencies USD 0 us-gaap/2024
0001178670-25-000052 20241231 Common Stock Par Or Stated Value Per Share 0.0100 USD 0 us-gaap/2024
0001178670-25-000052 20250331 Common Stock Value 1303000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20250331 Deferred Income Tax Expense Benefit 9639000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20240331 Depreciation Amortization And Accretion Net 13517000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20250331 Increase Decrease In Accounts Payable And Accrued Liabilities -155737000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20250331 Increase Decrease In Accounts Receivable 7434000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20250331 Increase Decrease In Prepaid Deferred Expense And Other Assets 32769000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20250331 Inventory Net 65581000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20250331 Liabilities And Stockholders Equity 4213811000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20250331 Liabilities Current 1075623000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20250331 Net Cash Provided By Used In Investing Activities 113769000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20241231 Operating Lease Liability Noncurrent 229541000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20250331 Operating Lease Liability Noncurrent 230061000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20250331 Other Comprehensive Income Loss Net Of Tax -2999000.0000 USD 1 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001178670-25-000052 20240331 Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Reclassification Adjustments Net Of Tax -33000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20240331 Payments For Proceeds From Derivative Instrument Financing Activities -3052000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20250331 Payments To Acquire Property Plant And Equipment 8970000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20250331 Preferred Stock Shares Issued 0.0000 shares 0 us-gaap/2024
0001178670-25-000052 20240331 Research And Development Expense 125510000.0000 USD 1 us-gaap/2024 Research And Development Expense= Clinical Research And Outside Services;
0001178670-25-000052 20240331 Revenue From Contract With Customer Excluding Assessed Tax 494333000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20250331 Revenue From Contract With Customer Excluding Assessed Tax 13800000.0000 USD 1 us-gaap/2024 Counterparty Name= Regeneron Pharmaceuticals Incorporation; Product Or Service= Research Services Obligation; Type Of Arrangement= Global Strategic Collaboration;
0001178670-25-000052 20250331 Revenue From Contract With Customer Excluding Assessed Tax 6996000.0000 USD 1 us-gaap/2024 Geographical= Non U S Or Europe; Product Or Service= O X L U M O;
0001178670-25-000052 20250331 Revenue From Contract With Customer Excluding Assessed Tax 359481000.0000 USD 1 us-gaap/2024 Product Or Service= T T R;
0001178670-25-000052 20240331 Share Based Compensation 45347000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20240331 Stockholders Equity -2720000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Defined Benefit Plans Adjustment;
0001178670-25-000052 20241231 Stockholders Equity 67088000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20241231 Stockholders Equity 979000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Translation Adjustment;
0001178670-25-000052 20240331 Stock Issued During Period Shares Share Based Compensation Gross 446000.0000 shares 1 us-gaap/2024 Equity Components= Common Stock;
0001178670-25-000052 20250331 Stock Issued During Period Value Share Based Compensation Gross 6000.0000 USD 1 us-gaap/2024 Equity Components= Common Stock;
0001178670-25-000052 20250331 Equity Securities Fv Ni Gain Loss -956000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20250331 Change In Fair Value Of Liability Obligation -58891000.0000 USD 1 0001178670-25-000052
0001178670-25-000052 20250331 Commitments And Contingencies USD 0 us-gaap/2024
0001178670-25-000052 20250331 Common Stock Par Or Stated Value Per Share 0.0100 USD 0 us-gaap/2024
0001178670-25-000052 20240331 Common Stock Shares Outstanding 126463000.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0001178670-25-000052 20240331 Comprehensive Income Net Of Tax -69548000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20240331 Earnings Per Share Diluted -0.5200 USD 1 us-gaap/2024
0001178670-25-000052 20241231 Equity Securities Fv Ni 8156000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20240331 Net Income Loss -65935000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20250331 Nonoperating Income Expense -59673000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20240331 Operating Income Loss -43435000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20250331 Operating Lease Liability Current 46011000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20250331 Other Assets Noncurrent 73820000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20250331 Other Nonoperating Income Expense -49700000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20250331 Preferred Stock Par Or Stated Value Per Share 0.0100 USD 0 us-gaap/2024
0001178670-25-000052 20250331 Preferred Stock Shares Outstanding 0.0000 shares 0 us-gaap/2024
0001178670-25-000052 20241231 Prepaid Expense And Other Assets Current 116964000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20250331 Prepaid Expense And Other Assets Current 152420000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20240331 Research And Development Expense 18100000.0000 USD 1 us-gaap/2024 Counterparty Name= Roche; Type Of Arrangement= Roche Collaboration And License Agreement;
0001178670-25-000052 20240331 Research And Development Expense 39061000.0000 USD 1 us-gaap/2024 Research And Development Expense= Occupancy And All Other Costs;
0001178670-25-000052 20250331 Research And Development Expense 99187000.0000 USD 1 us-gaap/2024 Research And Development Expense= Compensation And Related;
0001178670-25-000052 20241231 Retained Earnings Accumulated Deficit -7287748000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20240331 Revenue From Contract With Customer Excluding Assessed Tax 2588000.0000 USD 1 us-gaap/2024 Counterparty Name= Other Collaborations; Type Of Arrangement= Collaborative Arrangement;
0001178670-25-000052 20240331 Revenue From Contract With Customer Excluding Assessed Tax 26764000.0000 USD 1 us-gaap/2024 Counterparty Name= Regeneron Pharmaceuticals Incorporation; Type Of Arrangement= Collaborative Arrangement;
0001178670-25-000052 20240331 Revenue From Contract With Customer Excluding Assessed Tax 44690000.0000 USD 1 us-gaap/2024 Geographical= Europe; Product Or Service= O N P A T T R O;
0001178670-25-000052 20240331 Revenue From Contract With Customer Excluding Assessed Tax 21427000.0000 USD 1 us-gaap/2024 Geographical= Europe; Product Or Service= O X L U M O;
0001178670-25-000052 20240331 Revenue From Contract With Customer Excluding Assessed Tax 21270000.0000 USD 1 us-gaap/2024 Geographical= Non U S Or Europe; Product Or Service= Amvuttra;
0001178670-25-000052 20240331 Revenue From Contract With Customer Excluding Assessed Tax 10622000.0000 USD 1 us-gaap/2024 Product Or Service= Royalty;
0001178670-25-000052 20240331 Revenue From Contract With Customer Excluding Assessed Tax 118548000.0000 USD 1 us-gaap/2024 Type Of Arrangement= Collaborative Arrangement;
0001178670-25-000052 20250331 Revenue From Contract With Customer Excluding Assessed Tax 31090000.0000 USD 1 us-gaap/2024 Counterparty Name= Other Collaborations; Type Of Arrangement= Collaborative Arrangement;
0001178670-25-000052 20250331 Revenue From Contract With Customer Excluding Assessed Tax 20984000.0000 USD 1 us-gaap/2024 Geographical= Europe; Product Or Service= O X L U M O;
0001178670-25-000052 20250331 Revenue From Contract With Customer Excluding Assessed Tax 43794000.0000 USD 1 us-gaap/2024 Geographical= U S; Product Or Service= G I V L A A R I;
0001178670-25-000052 20250331 Revenue From Contract With Customer Excluding Assessed Tax 99185000.0000 USD 1 us-gaap/2024 Type Of Arrangement= Collaborative Arrangement;
0001178670-25-000052 20241231 Royalty Liability Noncurrent 1334353000.0000 USD 0 0001178670-25-000052
0001178670-25-000052 20240331 Selling General And Administrative Expense 117341000.0000 USD 1 us-gaap/2024 Selling General And Administrative Expense= Compensation And Related;
0001178670-25-000052 20240331 Selling General And Administrative Expense 36697000.0000 USD 1 us-gaap/2024 Selling General And Administrative Expense= Occupancy And All Other Costs;
0001178670-25-000052 20250331 Selling General And Administrative Expense 239949000.0000 USD 1 us-gaap/2024
0001178670-25-000052 20231231 Stockholders Equity -220644000.0000 USD 0 us-gaap/2024
0001178670-25-000052 20240331 Stockholders Equity 6881977000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001178670-25-000052 20250331 Stockholders Equity -37517000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001178670-25-000052 20250331 Stockholders Equity -7345227000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0001178670-25-000052 20240331 Stock Issued During Period Shares Stock Options Exercised 223000.0000 shares 1 us-gaap/2024 Equity Components= Common Stock;
0001178670-25-000052 20250331 Stock Issued During Period Shares Stock Options Exercised 423000.0000 shares 1 us-gaap/2024 Equity Components= Common Stock;
0001178670-25-000052 20240331 Stock Issued During Period Value Share Based Compensation Gross 4000.0000 USD 1 us-gaap/2024 Equity Components= Common Stock;
0001178670-25-000052 20250331 Stock Issued During Period Value Stock Options Exercised 4000.0000 USD 1 us-gaap/2024 Equity Components= Common Stock;
0001178670-25-000052 20250331 Weighted Average Number Of Diluted Shares Outstanding 129676000.0000 shares 1 us-gaap/2024

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
tag The unique identifier (name) for a tag in a specific taxonomy release.
version For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined.
ddate The end date for the data value, rounded to the nearest month end.
qtrs The count of the number of quarters represented by the data value, rounded to the nearest whole number. “0” indicates it is a point-in-time value.
uom The unit of measure for the value.
segments Tags used to represent axis and member reporting.
coreg If specified, indicates a specific co-registrant, the parent company, or other entity (e.g., guarantor). NULL indicates the consolidated entity.
value The value. This is not scaled, it is as found in the Interactive Data file, but is limited to four digits to the right of the decimal point.
footnote The text of any superscripted footnotes on the value, as shown on the statement page, truncated to 512 characters, or if there is no footnote, then this field will be blank.

Tags

tag version custom abstract datatype iord crdr tlabel doc
Increase Decrease In Accounts Receivable us-gaap/2024 0 0 monetary D C Increase (Decrease) in Accounts Receivable The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
Stock Issued During Period Value Stock Options Exercised us-gaap/2024 0 0 monetary D C Stock Issued During Period, Value, Stock Options Exercised Value of stock issued as a result of the exercise of stock options.
Change In Fair Value Of Liability Obligation 0001178670-25-000052 1 0 monetary D C Change In Fair Value Of Liability Obligation Change in fair value of liability obligation.
Assets Current us-gaap/2024 0 0 monetary I D Assets, Current Amount of asset recognized for present right to economic benefit, classified as current.
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2024 0 0 monetary I D Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Operating Lease Liability Current us-gaap/2024 0 0 monetary I C Operating Lease, Liability, Current Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.
Revenue From Contract With Customer Excluding Assessed Tax us-gaap/2024 0 0 monetary D C Revenue from Contract with Customer, Excluding Assessed Tax Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
Royalty Liability Noncurrent 0001178670-25-000052 1 0 monetary I C Royalty Liability, Noncurrent Royalty Liability, Noncurrent
Comprehensive Income Net Of Tax us-gaap/2024 0 0 monetary D C Comprehensive Income (Loss), Net of Tax, Attributable to Parent Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
Payments To Acquire Property Plant And Equipment us-gaap/2024 0 0 monetary D C Payments to Acquire Property, Plant, and Equipment The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
Right Of Use Asset Obtained In Exchange For Operating Lease Liability us-gaap/2024 0 0 monetary D D Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Amount of increase in right-of-use asset obtained in exchange for operating lease liability.
Deferred Income Tax Assets Net us-gaap/2024 0 0 monetary I D Deferred Income Tax Assets, Net Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.
Equity Securities Fv Ni us-gaap/2024 0 0 monetary I D Equity Securities, FV-NI, Current Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.
Available For Sale Securities Debt Securities Current us-gaap/2024 0 0 monetary I D Debt Securities, Available-for-Sale, Current Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest us-gaap/2024 0 0 monetary D C Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
Increase Decrease In Contract With Customer Liability us-gaap/2024 0 0 monetary D D Increase (Decrease) in Contract with Customer, Liability Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.
Payments For Proceeds From Derivative Instrument Financing Activities us-gaap/2024 0 0 monetary D C Payments for (Proceeds from) Derivative Instrument, Financing Activities The net cash outflow or inflow from derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments.
Liabilities us-gaap/2024 0 0 monetary I C Liabilities Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.
Liabilities And Stockholders Equity us-gaap/2024 0 0 monetary I C Liabilities and Equity Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Reclassification Adjustments Net Of Tax us-gaap/2024 0 0 monetary D D Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment, after Tax Amount, after tax, before reclassification adjustment, of (increase) decrease in accumulated other comprehensive income of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax us-gaap/2024 0 0 monetary D C OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.
Retained Earnings Accumulated Deficit us-gaap/2024 0 0 monetary I C Retained Earnings (Accumulated Deficit) Amount of accumulated undistributed earnings (deficit).
Stock Issued During Period Value Share Based Compensation Gross us-gaap/2024 0 0 monetary D C Shares Issued, Value, Share-Based Payment Arrangement, before Forfeiture Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).
Accounts Receivable Net Current us-gaap/2024 0 0 monetary I D Accounts Receivable, after Allowance for Credit Loss, Current Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Common Stock Par Or Stated Value Per Share us-gaap/2024 0 0 perShare I Common Stock, Par or Stated Value Per Share Face amount or stated value per share of common stock.
Common Stock Shares Outstanding us-gaap/2024 0 0 shares I Common Stock, Shares, Outstanding Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
Derivative Liabilities Current us-gaap/2024 0 0 monetary I C Derivative Liability, Current Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.
Income Tax Expense Benefit us-gaap/2024 0 0 monetary D D Income Tax Expense (Benefit) Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Accrued Liabilities Current us-gaap/2024 0 0 monetary I C Accrued Liabilities, Current Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Net Income Loss us-gaap/2024 0 0 monetary D C Net Income (Loss) Attributable to Parent The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Other Operating Activities Cash Flow Statement us-gaap/2024 0 0 monetary D D Other Operating Activities, Cash Flow Statement Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).
Restricted Investments Noncurrent us-gaap/2024 0 0 monetary I D Restricted Investments, Noncurrent This element represents the noncurrent portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions.
Stockholders Equity us-gaap/2024 0 0 monetary I C Equity, Attributable to Parent Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.
Weighted Average Number Of Diluted Shares Outstanding us-gaap/2024 0 0 shares D Weighted Average Number of Shares Outstanding, Diluted The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
Accumulated Other Comprehensive Income Loss Net Of Tax us-gaap/2024 0 0 monetary I C Accumulated Other Comprehensive Income (Loss), Net of Tax Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.
Assets us-gaap/2024 0 0 monetary I D Assets Amount of asset recognized for present right to economic benefit.
Common Stock Shares Issued us-gaap/2024 0 0 shares I Common Stock, Shares, Issued Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
Cost Of Goods And Services Sold us-gaap/2024 0 0 monetary D D Cost of Goods and Services Sold The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.
Depreciation Amortization And Accretion Net us-gaap/2024 0 0 monetary D D Depreciation, Amortization and Accretion, Net The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.
Earnings Per Share Diluted us-gaap/2024 0 0 perShare D Earnings Per Share, Diluted The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2024 0 0 monetary D D Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Operating Lease Right Of Use Asset us-gaap/2024 0 0 monetary I D Operating Lease, Right-of-Use Asset Amount of lessee's right to use underlying asset under operating lease.
Other Assets Noncurrent us-gaap/2024 0 0 monetary I D Other Assets, Noncurrent Amount of noncurrent assets classified as other.
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options us-gaap/2024 0 0 monetary D D Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.
Convertible Debt Noncurrent us-gaap/2024 0 0 monetary I C Convertible Debt, Noncurrent Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.
Derivative Liabilities Noncurrent us-gaap/2024 0 0 monetary I C Derivative Liability, Noncurrent Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.
Interest Expense Nonoperating us-gaap/2024 0 0 monetary D D Interest Expense, Nonoperating Amount of interest expense classified as nonoperating.
Liabilities Current us-gaap/2024 0 0 monetary I C Liabilities, Current Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
Payments To Acquire Available For Sale Securities Debt us-gaap/2024 0 0 monetary D C Payments to Acquire Debt Securities, Available-for-Sale Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
Preferred Stock Shares Issued us-gaap/2024 0 0 shares I Preferred Stock, Shares Issued Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.
Proceeds From Sale And Maturity Of Marketable Securities us-gaap/2024 0 0 monetary D D Proceeds from Sale and Maturity of Marketable Securities The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.
Selling General And Administrative Expense us-gaap/2024 0 0 monetary D D Selling, General and Administrative Expense The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.
Share Based Compensation us-gaap/2024 0 0 monetary D D Share-Based Payment Arrangement, Noncash Expense Amount of noncash expense for share-based payment arrangement.
Costs And Expenses us-gaap/2024 0 0 monetary D D Costs and Expenses Total costs of sales and operating expenses for the period.
Royalty Liability Current 0001178670-25-000052 1 0 monetary I C Royalty Liability, Current Royalty Liability, Current
Cash And Cash Equivalents At Carrying Value us-gaap/2024 0 0 monetary I D Cash and Cash Equivalents, at Carrying Value Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
Income Taxes Paid Net us-gaap/2024 0 0 monetary D C Income Taxes Paid, Net Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.
Increase Decrease In Inventories us-gaap/2024 0 0 monetary D C Increase (Decrease) in Inventories The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
Increase Decrease In Prepaid Deferred Expense And Other Assets us-gaap/2024 0 0 monetary D C Increase (Decrease) in Prepaid Expense and Other Assets Amount of increase (decrease) in prepaid expenses, and assets classified as other.
Nonoperating Income Expense us-gaap/2024 0 0 monetary D C Nonoperating Income (Expense) The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Other Comprehensive Income Loss Net Of Tax us-gaap/2024 0 0 monetary D C Other Comprehensive Income (Loss), Net of Tax Amount after tax and reclassification adjustments of other comprehensive income (loss).
Preferred Stock Value us-gaap/2024 0 0 monetary I C Preferred Stock, Value, Issued Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
Stock Issued During Period Shares Share Based Compensation Gross us-gaap/2024 0 0 shares D Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).
Deferred Income Tax Expense Benefit us-gaap/2024 0 0 monetary D D Deferred Income Tax Expense (Benefit) Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
Net Cash Provided By Used In Operating Activities us-gaap/2024 0 0 monetary D Net Cash Provided by (Used in) Operating Activities Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
Operating Income Loss us-gaap/2024 0 0 monetary D C Operating Income (Loss) The net result for the period of deducting operating expenses from operating revenues.
Other Liabilities Noncurrent us-gaap/2024 0 0 monetary I C Other Liabilities, Noncurrent Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.
Prepaid Expense And Other Assets Current us-gaap/2024 0 0 monetary I D Prepaid Expense and Other Assets, Current Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
Non Cash Interest Expense On Sale Of Future Royalties 0001178670-25-000052 1 0 monetary D D Non-Cash Interest Expense On Sale Of Future Royalties Non-Cash Interest Expense On Sale Of Future Royalties
Inventory Net us-gaap/2024 0 0 monetary I D Inventory, Net Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
Capital Expenditures Incurred But Not Yet Paid us-gaap/2024 0 0 monetary D C Capital Expenditures Incurred but Not yet Paid Future cash outflow to pay for purchases of fixed assets that have occurred.
Common Stock Value us-gaap/2024 0 0 monetary I C Common Stock, Value, Issued Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
Proceeds From Sale Of Restricted Investments us-gaap/2024 0 0 monetary D D Proceeds from Sale of Restricted Investments The cash inflow associated with the sale of investments that are pledged or subject to withdrawal restrictions during the period.
Research And Development Expense us-gaap/2024 0 0 monetary D D Research and Development Expense Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.
Cost Of Collaboration Manufacturing And Royalties 0001178670-25-000052 1 0 monetary D D Cost Of Collaboration Manufacturing And Royalties Cost Of Collaboration Manufacturing And Royalties
Additional Paid In Capital Common Stock us-gaap/2024 0 0 monetary I C Additional Paid in Capital, Common Stock Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect us-gaap/2024 0 0 monetary D D Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Commitments And Contingencies us-gaap/2024 0 0 monetary I C Commitments and Contingencies Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
Common Stock Shares Authorized us-gaap/2024 0 0 shares I Common Stock, Shares Authorized The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
Equity Securities Fv Ni Gain Loss us-gaap/2024 0 0 monetary D C Equity Securities, FV-NI, Gain (Loss) Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).
Interest Paid Net us-gaap/2024 0 0 monetary D C Interest Paid, Excluding Capitalized Interest, Operating Activities Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.
Net Cash Provided By Used In Financing Activities us-gaap/2024 0 0 monetary D D Net Cash Provided by (Used in) Financing Activities Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax us-gaap/2024 0 0 monetary D C Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.
Payments To Acquire Restricted Investments us-gaap/2024 0 0 monetary D C Payments to Acquire Restricted Investments The cash outflow to acquire investments (not to include restricted cash) that are pledged or subject to withdrawal restrictions.
Preferred Stock Par Or Stated Value Per Share us-gaap/2024 0 0 perShare I Preferred Stock, Par or Stated Value Per Share Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value us-gaap/2024 0 0 monetary D C APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.
Accounts Payable Current us-gaap/2024 0 0 monetary I C Accounts Payable, Current Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Contract With Customer Liability Current us-gaap/2024 0 0 monetary I C Contract with Customer, Liability, Current Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.
Earnings Per Share Basic us-gaap/2024 0 0 perShare D Earnings Per Share, Basic The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
Increase Decrease In Accounts Payable And Accrued Liabilities us-gaap/2024 0 0 monetary D D Increase (Decrease) in Accounts Payable and Accrued Liabilities The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.
Investment Income Interest us-gaap/2024 0 0 monetary D C Investment Income, Interest Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.
Net Cash Provided By Used In Investing Activities us-gaap/2024 0 0 monetary D D Net Cash Provided by (Used in) Investing Activities Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
Other Nonoperating Income Expense us-gaap/2024 0 0 monetary D C Other Nonoperating Income (Expense) Amount of income (expense) related to nonoperating activities, classified as other.
Preferred Stock Shares Authorized us-gaap/2024 0 0 shares I Preferred Stock, Shares Authorized The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
Preferred Stock Shares Outstanding us-gaap/2024 0 0 shares I Preferred Stock, Shares Outstanding Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
Stock Issued During Period Shares Stock Options Exercised us-gaap/2024 0 0 shares D Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Number of share options (or share units) exercised during the current period.
Operating Lease Liability Noncurrent us-gaap/2024 0 0 monetary I C Operating Lease, Liability, Noncurrent Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
Property Plant And Equipment Net us-gaap/2024 0 0 monetary I D Property, Plant and Equipment, Net Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
Weighted Average Number Of Shares Outstanding Basic us-gaap/2024 0 0 shares D Weighted Average Number of Shares Outstanding, Basic Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.

Description
Field Name Field Description
tag The unique identifier (name) for a tag in a specific taxonomy release.
version For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined.
custom 1 if tag is custom (version=adsh), 0 if it is standard. Note: This flag is technically redundant with the version and adsh columns.
abstract 1 if the tag is not used to represent a numeric fact.
datatype If abstract=1, then NULL, otherwise the data type (e.g., monetary) for the tag.
iord If abstract=1, then NULL; otherwise, “I” if the value is a point-in time, or “D” if the value is a duration.
crdr If datatype = monetary, then the tag’s natural accounting balance (debit or credit); if not defined, then NULL.
tlabel If a standard tag, then the label text provided by the taxonomy, otherwise the text provided by the filer. A tag which had neither would have a NULL value here.
doc The detailed definition for the tag. If a standard tag, then the text provided by the taxonomy, otherwise the text assigned by the filer. Some tags have neither, and this field is NULL.

Presentation of Statements

adsh report line stmt inpth rfile tag version plabel negating
0001178670-25-000052 2 9 BS 0 H Assets Current us-gaap/2024 Total current assets 0
0001178670-25-000052 2 3 BS 0 H Cash And Cash Equivalents At Carrying Value us-gaap/2024 Cash and cash equivalents 0
0001178670-25-000052 2 4 BS 0 H Available For Sale Securities Debt Securities Current us-gaap/2024 Marketable debt securities 0
0001178670-25-000052 2 5 BS 0 H Equity Securities Fv Ni us-gaap/2024 Marketable equity securities 0
0001178670-25-000052 2 6 BS 0 H Accounts Receivable Net Current us-gaap/2024 Accounts receivable, net 0
0001178670-25-000052 2 7 BS 0 H Inventory Net us-gaap/2024 Inventory 0
0001178670-25-000052 2 8 BS 0 H Prepaid Expense And Other Assets Current us-gaap/2024 Prepaid expenses and other current assets 0
0001178670-25-000052 2 10 BS 0 H Property Plant And Equipment Net us-gaap/2024 Property, plant and equipment, net 0
0001178670-25-000052 2 11 BS 0 H Operating Lease Right Of Use Asset us-gaap/2024 Operating lease right-of-use assets 0
0001178670-25-000052 2 12 BS 0 H Deferred Income Tax Assets Net us-gaap/2024 Deferred tax assets 0
0001178670-25-000052 2 13 BS 0 H Restricted Investments Noncurrent us-gaap/2024 Restricted investments 0
0001178670-25-000052 2 14 BS 0 H Other Assets Noncurrent us-gaap/2024 Other assets 0
0001178670-25-000052 2 15 BS 0 H Assets us-gaap/2024 Total assets 0
0001178670-25-000052 2 18 BS 0 H Accounts Payable Current us-gaap/2024 Accounts payable 0
0001178670-25-000052 2 19 BS 0 H Accrued Liabilities Current us-gaap/2024 Accrued expenses 0
0001178670-25-000052 2 20 BS 0 H Operating Lease Liability Current us-gaap/2024 Operating lease liabilities 0
0001178670-25-000052 2 21 BS 0 H Contract With Customer Liability Current us-gaap/2024 Deferred revenue 0
0001178670-25-000052 2 22 BS 0 H Royalty Liability Current 0001178670-25-000052 Liability related to the sale of future royalties 0
0001178670-25-000052 2 23 BS 0 H Derivative Liabilities Current us-gaap/2024 Development derivative liability 0
0001178670-25-000052 2 24 BS 0 H Liabilities Current us-gaap/2024 Total current liabilities 0
0001178670-25-000052 2 25 BS 0 H Operating Lease Liability Noncurrent us-gaap/2024 Operating lease liabilities, net of current portion 0
0001178670-25-000052 2 26 BS 0 H Convertible Debt Noncurrent us-gaap/2024 Convertible debt 0
0001178670-25-000052 2 27 BS 0 H Royalty Liability Noncurrent 0001178670-25-000052 Liability related to the sale of future royalties, net of current portion 0
0001178670-25-000052 2 28 BS 0 H Derivative Liabilities Noncurrent us-gaap/2024 Development derivative liability, net of current portion 0
0001178670-25-000052 2 29 BS 0 H Other Liabilities Noncurrent us-gaap/2024 Other liabilities 0
0001178670-25-000052 2 30 BS 0 H Liabilities us-gaap/2024 Total liabilities 0
0001178670-25-000052 2 31 BS 0 H Commitments And Contingencies us-gaap/2024 Commitments and contingencies (Note 12) 0
0001178670-25-000052 2 33 BS 0 H Preferred Stock Value us-gaap/2024 Preferred stock, $0.01 par value per share, 5,000 shares authorized and no shares issued and outstanding as of March 31, 2025 and December 31, 2024 0
0001178670-25-000052 2 34 BS 0 H Common Stock Value us-gaap/2024 Common stock, $0.01 par value per share, 250,000 shares authorized; 130,311 shares issued and outstanding as of March 31, 2025; 129,294 shares issued and outstanding as of December 31, 2024 0
0001178670-25-000052 2 35 BS 0 H Additional Paid In Capital Common Stock us-gaap/2024 Additional paid-in capital 0
0001178670-25-000052 2 36 BS 0 H Accumulated Other Comprehensive Income Loss Net Of Tax us-gaap/2024 Accumulated other comprehensive loss 0
0001178670-25-000052 2 37 BS 0 H Retained Earnings Accumulated Deficit us-gaap/2024 Accumulated deficit 0
0001178670-25-000052 2 38 BS 0 H Stockholders Equity us-gaap/2024 Total stockholders' equity 0
0001178670-25-000052 2 39 BS 0 H Liabilities And Stockholders Equity us-gaap/2024 Total liabilities and stockholders' equity 0
0001178670-25-000052 3 1 BS 1 H Preferred Stock Par Or Stated Value Per Share us-gaap/2024 Preferred stock, par value (in dollars per share) 0
0001178670-25-000052 3 2 BS 1 H Preferred Stock Shares Authorized us-gaap/2024 Preferred stock, shares authorized (in shares) 0
0001178670-25-000052 3 3 BS 1 H Preferred Stock Shares Issued us-gaap/2024 Preferred stock, shares issued (in shares) 0
0001178670-25-000052 3 4 BS 1 H Preferred Stock Shares Outstanding us-gaap/2024 Preferred stock, shares outstanding (in shares) 0
0001178670-25-000052 3 5 BS 1 H Common Stock Par Or Stated Value Per Share us-gaap/2024 Common stock, par value (in dollars per share) 0
0001178670-25-000052 3 6 BS 1 H Common Stock Shares Authorized us-gaap/2024 Common stock, shares authorized (in shares) 0
0001178670-25-000052 3 7 BS 1 H Common Stock Shares Issued us-gaap/2024 Common stock, shares issued (in shares) 0
0001178670-25-000052 3 8 BS 1 H Common Stock Shares Outstanding us-gaap/2024 Common stock, shares outstanding (in shares) 0
0001178670-25-000052 4 9 IS 0 H Revenue From Contract With Customer Excluding Assessed Tax us-gaap/2024 Total revenues 0
0001178670-25-000052 4 11 IS 0 H Cost Of Goods And Services Sold us-gaap/2024 Cost of goods sold 0
0001178670-25-000052 4 12 IS 0 H Cost Of Collaboration Manufacturing And Royalties 0001178670-25-000052 Cost of collaborations and royalties 0
0001178670-25-000052 4 13 IS 0 H Research And Development Expense us-gaap/2024 Research and development 0
0001178670-25-000052 4 14 IS 0 H Selling General And Administrative Expense us-gaap/2024 Selling, general and administrative 0
0001178670-25-000052 4 15 IS 0 H Costs And Expenses us-gaap/2024 Total operating costs and expenses 0
0001178670-25-000052 4 16 IS 0 H Operating Income Loss us-gaap/2024 Income (loss) from operations 0
0001178670-25-000052 4 18 IS 0 H Interest Expense Nonoperating us-gaap/2024 Interest expense 1
0001178670-25-000052 4 19 IS 0 H Investment Income Interest us-gaap/2024 Interest income 0
0001178670-25-000052 4 20 IS 0 H Other Nonoperating Income Expense us-gaap/2024 Other expense, net 0
0001178670-25-000052 4 21 IS 0 H Nonoperating Income Expense us-gaap/2024 Total other expense, net 0
0001178670-25-000052 4 22 IS 0 H Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest us-gaap/2024 Loss before income taxes 0
0001178670-25-000052 4 23 IS 0 H Income Tax Expense Benefit us-gaap/2024 Provision for income taxes 1
0001178670-25-000052 4 24 IS 0 H Net Income Loss us-gaap/2024 Net loss 0
0001178670-25-000052 4 25 IS 0 H Earnings Per Share Basic us-gaap/2024 Net loss per common share - basic (in dollars per share) 0
0001178670-25-000052 4 26 IS 0 H Earnings Per Share Diluted us-gaap/2024 Net loss per common share - diluted (in dollars per share) 0
0001178670-25-000052 4 27 IS 0 H Weighted Average Number Of Shares Outstanding Basic us-gaap/2024 Weighted-average common shares used to compute - basic (in shares) 0
0001178670-25-000052 4 28 IS 0 H Weighted Average Number Of Diluted Shares Outstanding us-gaap/2024 Weighted-average common shares used to compute - diluted (in shares) 0
0001178670-25-000052 4 30 IS 0 H Net Income Loss us-gaap/2024 Net loss 0
0001178670-25-000052 4 32 IS 0 H Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax us-gaap/2024 Unrealized gain (loss) on marketable securities 0
0001178670-25-000052 4 33 IS 0 H Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax us-gaap/2024 Foreign currency translation loss 0
0001178670-25-000052 4 34 IS 0 H Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Reclassification Adjustments Net Of Tax us-gaap/2024 Defined benefit pension plans, net of tax 1
0001178670-25-000052 4 35 IS 0 H Other Comprehensive Income Loss Net Of Tax us-gaap/2024 Total other comprehensive loss 0
0001178670-25-000052 4 36 IS 0 H Comprehensive Income Net Of Tax us-gaap/2024 Comprehensive loss 0
0001178670-25-000052 5 10 EQ 0 H Common Stock Shares Outstanding us-gaap/2024 Beginning balance (in shares) 0
0001178670-25-000052 5 11 EQ 0 H Stockholders Equity us-gaap/2024 Beginning balance 0
0001178670-25-000052 5 12 EQ 0 H Stock Issued During Period Shares Stock Options Exercised us-gaap/2024 Exercise of common stock options, net of tax withholdings (in shares) 0
0001178670-25-000052 5 13 EQ 0 H Stock Issued During Period Value Stock Options Exercised us-gaap/2024 Exercise of common stock options, net of tax withholdings 0
0001178670-25-000052 5 14 EQ 0 H Stock Issued During Period Shares Share Based Compensation Gross us-gaap/2024 Issuance of common stock under equity plans (in shares) 0
0001178670-25-000052 5 15 EQ 0 H Stock Issued During Period Value Share Based Compensation Gross us-gaap/2024 Issuance of common stock under equity plans 0
0001178670-25-000052 5 16 EQ 0 H Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value us-gaap/2024 Stock-based compensation expense 0
0001178670-25-000052 5 17 EQ 0 H Other Comprehensive Income Loss Net Of Tax us-gaap/2024 Other comprehensive loss 0
0001178670-25-000052 5 18 EQ 0 H Net Income Loss us-gaap/2024 Net loss 0
0001178670-25-000052 5 19 EQ 0 H Common Stock Shares Outstanding us-gaap/2024 Ending balance (in shares) 0
0001178670-25-000052 5 20 EQ 0 H Stockholders Equity us-gaap/2024 Ending balance 0
0001178670-25-000052 6 2 CF 0 H Net Income Loss us-gaap/2024 Net loss 0
0001178670-25-000052 6 4 CF 0 H Depreciation Amortization And Accretion Net us-gaap/2024 Depreciation and amortization 0
0001178670-25-000052 6 5 CF 0 H Non Cash Interest Expense On Sale Of Future Royalties 0001178670-25-000052 Non-cash interest expense on liability related to the sale of future royalties 0
0001178670-25-000052 6 6 CF 0 H Share Based Compensation us-gaap/2024 Stock-based compensation 0
0001178670-25-000052 6 7 CF 0 H Equity Securities Fv Ni Gain Loss us-gaap/2024 Unrealized loss (gain) on marketable equity securities 1
0001178670-25-000052 6 8 CF 0 H Change In Fair Value Of Liability Obligation 0001178670-25-000052 Change in fair value of development derivative liability 1
0001178670-25-000052 6 9 CF 0 H Deferred Income Tax Expense Benefit us-gaap/2024 Deferred income taxes 0
0001178670-25-000052 6 10 CF 0 H Other Operating Activities Cash Flow Statement us-gaap/2024 Other 0
0001178670-25-000052 6 12 CF 0 H Increase Decrease In Accounts Receivable us-gaap/2024 Accounts receivable, net 1
0001178670-25-000052 6 13 CF 0 H Increase Decrease In Inventories us-gaap/2024 Inventory 1
0001178670-25-000052 6 14 CF 0 H Increase Decrease In Prepaid Deferred Expense And Other Assets us-gaap/2024 Prepaid expenses and other assets 1
0001178670-25-000052 6 15 CF 0 H Increase Decrease In Accounts Payable And Accrued Liabilities us-gaap/2024 Accounts payable, accrued expenses and other liabilities 0
0001178670-25-000052 6 16 CF 0 H Increase Decrease In Contract With Customer Liability us-gaap/2024 Deferred revenue 0
0001178670-25-000052 6 17 CF 0 H Net Cash Provided By Used In Operating Activities us-gaap/2024 Net cash used in operating activities 0
0001178670-25-000052 6 19 CF 0 H Payments To Acquire Property Plant And Equipment us-gaap/2024 Purchases of property, plant and equipment 1
0001178670-25-000052 6 20 CF 0 H Payments To Acquire Available For Sale Securities Debt us-gaap/2024 Purchases of marketable securities 1
0001178670-25-000052 6 21 CF 0 H Proceeds From Sale And Maturity Of Marketable Securities us-gaap/2024 Sales and maturities of marketable securities 0
0001178670-25-000052 6 22 CF 0 H Proceeds From Sale Of Restricted Investments us-gaap/2024 Proceeds from maturity of restricted investments 0
0001178670-25-000052 6 23 CF 0 H Payments To Acquire Restricted Investments us-gaap/2024 Purchases of restricted investments 1
0001178670-25-000052 6 24 CF 0 H Net Cash Provided By Used In Investing Activities us-gaap/2024 Net cash provided by (used in) investing activities 0
0001178670-25-000052 6 26 CF 0 H Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options us-gaap/2024 Proceeds from exercise of stock options and other types of equity, net 0
0001178670-25-000052 6 27 CF 0 H Payments For Proceeds From Derivative Instrument Financing Activities us-gaap/2024 (Repayment of) proceeds from development derivative, net 1
0001178670-25-000052 6 28 CF 0 H Net Cash Provided By Used In Financing Activities us-gaap/2024 Net cash provided by financing activities 0
0001178670-25-000052 6 29 CF 0 H Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2024 Effect of exchange rate changes on cash, cash equivalents and restricted cash 0
0001178670-25-000052 6 30 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect us-gaap/2024 Net increase (decrease) in cash, cash equivalents and restricted cash 0
0001178670-25-000052 6 31 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2024 Cash, cash equivalents and restricted cash, beginning of period 0
0001178670-25-000052 6 32 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2024 Cash, cash equivalents and restricted cash, end of period 0
0001178670-25-000052 6 34 CF 0 H Interest Paid Net us-gaap/2024 Cash paid for interest 0
0001178670-25-000052 6 35 CF 0 H Income Taxes Paid Net us-gaap/2024 Cash paid for taxes 0
0001178670-25-000052 6 36 CF 0 H Right Of Use Asset Obtained In Exchange For Operating Lease Liability us-gaap/2024 Operating lease right-of-use assets obtained in exchange for new operating lease liabilities 0
0001178670-25-000052 6 38 CF 0 H Capital Expenditures Incurred But Not Yet Paid us-gaap/2024 Capital expenditures included in accounts payable and accrued expenses 0

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
report Represents the report grouping. This field corresponds to the statement (stmt) field, which indicates the type of statement. The numeric value refers to the “R file” as posted on the EDGAR Web site.
line Represents the tag’s presentation line order for a given report. Together with the statement and report field, presentation location, order and grouping can be derived.
stmt The financial statement location to which the value of the “report” field pertains.
inpth Value was presented “parenthetically” instead of in columns within the financial statements. For example: Receivables (net of allowance for bad debts of $200 in 2012) $700.
rfile The type of interactive data file rendered on the EDGAR web site, H = .htm file, X = .xml file.
tag The tag chosen by the filer for this line item.
version The taxonomy identifier if the tag is a standard tag, otherwise adsh.
plabel The text presented on the line item, also known as a “preferred” label.
negating Flag to indicate whether the plabel is negating.